Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Author Archives: Warren Woessner
Happy Birthday To Me – Patents4Life is Three!
Three years ago, when I started this Blog (or is it “Blawg”?), the hot topics were In re Kubin and the summary affirmance of Classen by the Fed. Cir. Today, along with the looming AIA regulations, Mayo v. Prometheus and … Continue reading
Posted in Uncategorized
Tagged AIA, AMP v. Myriad, AUTM, caraco, claussen, in re kubin, Mayo v Prometheus, St-Gobain Ceramics v. Myriad, Supreme Court, Warren Woessner
1 Comment
A Hidden Danger Under The EPC – The “Extension Trap”
Provided to us by Dr. Stefan Danner of DHS Patentanwalts GmbH, find below the current issue of the biotech IP newsletter dealing with recent EPO case law on Article 123(2)(3) EPC. Extension Trap
Posted in Non-U.S. Practice
Tagged Dr. Steffan Danner, EPC, Patent Law, Warren Woessner
Leave a comment
Last Chapter In The “Corn Wars” Or Just The Latest?
On February 28, 2012, a three-judge panel of the Fed. Cir. ruled that the Board properly ruled that Monsanto prevailed in interference no. 105,728, involving the patent claims directed broadly to transgenic corn. (A copy of this ruling is found at … Continue reading
Bayer v. Lupin – Patenting The Label Redux
In my post of January 13, 2011, I discussed AstraZeneca LP v. Apotex, a Fed. Cir. decision in which AZ argued successfully that the proposed Apotex labeling for an anti-asthma drug would induce infringement if the generic were marketed with … Continue reading